Department of Dermatology, Kagoshima City Hospital, Kagoshima, Japan.
Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
J Dermatol. 2024 Jun;51(6):827-838. doi: 10.1111/1346-8138.17188. Epub 2024 Apr 11.
In Japan, cutaneous adverse events (AEs) following the coronavirus disease 2019 (COVID-19) vaccination have been frequently described; however, a larger case series and literature review are lacking. There is an urgent need for an extensive investigation of new cases and previous reports to provide a thorough body of information about post-COVID-19 immunization cutaneous AEs. We aimed to analyze patients with cutaneous AEs after COVID-19 vaccination in our hospital and review previous studies of cutaneous AEs. We analyzed post-COVID-19 vaccination cutaneous AEs in our department, the Japanese Registry, and previous literature. We enrolled 30 patients with cutaneous post-vaccination AEs in our department over 2 years (April 1, 2021, to March 31, 2023). We also confirmed cases registered in the Ministry of Health, Labor, and Welfare COVID-19 vaccine side effect reporting system (February 17, 2021-March 12, 2023). A total of 587 records were retrieved and 93 articles were included for data extraction. A total of 28 non-injection-site cutaneous AEs and two injection-site AEs were identified. Six (20.0%) patients developed new-onset erythematous eruptions, and five (16.7%) patients developed urticaria. Pruritic eruption, eczema, shingles, and sweating symptoms have also been reported. In previous studies on non-injection-site cutaneous AEs, individuals who received the BNT162b2 vaccine were older than those who received mRNA-1273 (P < 0.01). Cutaneous AEs were mostly nonsignificant and self-limiting reactions; however, rare, severe, or life-threatening AEs were also reported. Physicians should be aware of the various possible cutaneous AEs associated with the COVID-19 vaccination.
在日本，经常描述与 2019 年冠状病毒病（COVID-19）疫苗接种相关的皮肤不良事件（AE）；然而，缺乏更大的病例系列和文献综述。迫切需要对新病例和以前的报告进行广泛调查，以提供有关 COVID-19 免疫后皮肤 AE 的全面信息。我们旨在分析我院 COVID-19 疫苗接种后出现皮肤 AE 的患者，并回顾以前的皮肤 AE 研究。我们分析了我们科室、日本登记处和以前文献中的 COVID-19 疫苗接种后皮肤 AE。我们在 2 年（2021 年 4 月 1 日至 2023 年 3 月 31 日）期间共收治了 30 例接种 COVID-19 疫苗后出现皮肤 AE 的患者。我们还确认了厚生劳动省 COVID-19 疫苗不良反应报告系统（2021 年 2 月 17 日至 2023 年 3 月 12 日）中登记的病例。共检索到 587 条记录，提取了 93 篇文章的数据。共发现 28 例非注射部位皮肤 AE 和 2 例注射部位 AE。6 例（20.0%）患者出现新发红斑性皮疹，5 例（16.7%）患者出现荨麻疹。瘙痒性皮疹、湿疹、带状疱疹和出汗症状也有报道。在以前的非注射部位皮肤 AE 研究中，接种 BNT162b2 疫苗的个体比接种 mRNA-1273 的个体年龄更大（P<0.01）。皮肤 AE 大多是无明显意义的自限性反应；然而，也有报道称罕见、严重或危及生命的 AE。医生应了解与 COVID-19 疫苗接种相关的各种可能的皮肤 AE。
